AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca consolidated Total Revenue ($M) ($M)
Form 20-F & Form 6-K Consolidated Statement of Comprehensive Income (Postgres DB + Form 6-K Backfill)
Latest, Q2 2026
15,384
Period ended Jun 30, 2026
Change on a year earlier
+6.4%
14,457 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
24
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up consolidated total revenue ($m)
- Cost of sales ($M)2,523 · Q2 2026
- Gross profit ($M)12,861 · Q2 2026
- Distribution expense ($M)145 · Q2 2026
- Research and development expense ($M)4,053 · Q2 2026
- Selling, general and administrative expense ($M)5,651 · Q2 2026
- Other operating income and expense ($M)152 · Q2 2026
- Operating profit ($M)3,164 · Q2 2026
- Net finance expense ($M)-355 · Q2 2026
- Finance income ($M)80 · Q2 2026
- Finance expense ($M)435 · Q2 2026
- Share of after-tax losses of associates and joint ventures ($M)-10 · Q2 2026
- Profit before tax ($M)2,799 · Q2 2026
- Taxation ($M)291 · Q2 2026
- Profit for the period / Net income ($M)2,508 · Q2 2026
- Profit attributable to owners of the Parent ($M)2,507 · Q2 2026
- Basic earnings per $0.25 Ordinary Share ($)1.61 · Q2 2026
- Diluted earnings per $0.25 Ordinary Share ($)1.61 · Q2 2026
- Dividends declared per Ordinary Share ($)–
- Weighted average basic shares outstanding (millions)1,551 · Q2 2026
- Weighted average diluted shares outstanding (millions)1,560 · Q2 2026
Cite this data
StockData. (2026). AstraZeneca Consolidated Total Revenue ($M) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fin_rev
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.